Published in Leukemia on March 01, 2004
Asparagine synthetase chemotherapy. Annu Rev Biochem (2006) 1.82
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res (2014) 1.51
Recombinant L-Asparaginase from Zymomonas mobilis: A Potential New Antileukemic Agent Produced in Escherichia coli. PLoS One (2016) 1.40
Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab (2013) 1.26
Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem (2013) 1.12
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03
ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood (2011) 1.01
Engineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutants. PLoS One (2015) 0.80
Upregulation of asparagine synthetase and cell cycle arrest in t(12;21)-positive ALL. Leukemia (2005) 0.79
Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. Leukemia (2015) 0.77
Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice. J Biol Chem (2013) 0.76
Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Oncogene (2017) 0.75
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 2.55
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia (2007) 2.40
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia (2012) 1.93
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia (2012) 1.60
The MLL recombinome of acute leukemias. Leukemia (2006) 1.51
Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia (2009) 1.41
Typing of urinary JC virus DNA offers a novel means of tracing human migrations. Proc Natl Acad Sci U S A (1997) 1.30
NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia (2013) 1.16
Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia (2011) 1.15
Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia (2008) 1.08
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia (2010) 1.07
Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia (2006) 1.06
Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia (2011) 1.01
B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant (2008) 0.96
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia (2009) 0.96
Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia (2002) 0.95
Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring. Leukemia (2009) 0.88
Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia (2005) 0.88
Childhood secondary ALL after ALL treatment. Leukemia (2007) 0.87
No evidence for MLL/AF4 expression in normal cord blood samples. Blood (1999) 0.86
Transfer of genomics information to flow cytometry: expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia. Leukemia (2005) 0.85
Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. Leukemia (2013) 0.83
CD44 and CD27 delineate B-precursor stages with different recombination status and with an uneven distribution in nonmalignant and malignant hematopoiesis. Tissue Antigens (2007) 0.83
Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia (2009) 0.83
Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. Leukemia (2012) 0.82
Inv(11)(q21q23) fuses MLL to the Notch co-activator mastermind-like 2 in secondary T-cell acute lymphoblastic leukemia. Leukemia (2008) 0.81
Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing. Leukemia (2010) 0.81
Aberrant expression of KOR-SA3544 antigen in childhood acute lymphoblastic leukemia predicts TEL-AML1 negativity. The Pediatric Hematology Working Group in the Czech Republic. Leukemia (1998) 0.81
Acute lymphoblastic leukemia incidence during socioeconomic transition: selective increase in children from 1 to 4 years. Leukemia (2002) 0.80
TEL/AML1 positivity in childhood ALL: average or better prognosis? Czech Paediatric Haematology Working Group. Leukemia (1999) 0.80
Importance of using comparative genomic hybridization to improve detection of chromosomal changes in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet (2000) 0.80
Effect of histone deacetylase inhibitors on the cell nucleus and nucleolus of leukemic myeloblasts in vitro - a cytochemical study. Acta Histochem (2007) 0.78
Additional evidence of genetic changes in children with ALL and TEL/AML1 fusion gene. Leukemia (2002) 0.78
TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL. Leukemia (2005) 0.78
Mean diameter of nucleolar bodies in cultured human leukemic myeloblasts is mainly related to the S and G2 phase of the cell cycle. Eur J Histochem (2007) 0.75
Significantly lower relapse rate for TEL/AML1-positive ALL. Leukemia (1999) 0.75
To the nucleolar density and size in apoptotic human leukemic myeloblasts produced in vitro by Trichostatin A. Eur J Histochem (2008) 0.75
Are we ready to curtail testing for TEL/AML1 fusion? Pediatric Hematology Working Group in the Czech Republic. Leukemia (1999) 0.75
[Fluorescent in situ hybridization (FISH) in the diagnosis of acute childhood lymphatic leukemia (ALL)]. Cas Lek Cesk (2001) 0.75
Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia-impact on minimal residual disease detection. Leukemia (2012) 0.75
THY 1.1 and CD43 antigen expression on rat tumor cells. Transplant Proc (1993) 0.75
[Detection of monoclonality in childhood lymphoma with the polymerase chain reaction]. Cesk Patol (1998) 0.75
Treatment response and residual-disease monitoring in initial and relapsed TEL-AML1 positive childhood ALL. Leukemia (2001) 0.75
[Frequency view on genome changes testing]. Cas Lek Cesk (2006) 0.75
[Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic]. Cas Lek Cesk (2003) 0.75
Monitoring of minimal residual disease and mixed chimerism in a case of high-risk TEL/AML1+ acute lymphoblastic leukemia pre- and post-bone marrow transplantation. Czech Pediatric Haematology Working Group. Haematologica (2000) 0.75
[Treatment of adult acute lymphoblastic leukemia according to GMALL 07/2003 study protocol in the Czech Republic - the first experience]. Vnitr Lek (2010) 0.75
Temperature non-homogeneity in rapid airflow-based cycler significantly affects real-time PCR. Biotechniques (2002) 0.75
[Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia]. Vnitr Lek (2000) 0.75
Impact of TEL/AML1-positive patients on age distribution of childhood acute lymphoblastic leukemia in Czech Republic. Pediatric Hematology Working Group in Czech Republic. Leukemia (1998) 0.75
[Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study]. Klin Padiatr (2002) 0.75